Buscar en
Actas Urológicas Españolas (English Edition)
Toda la web
Inicio Actas Urológicas Españolas (English Edition) Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: 2 ...
Journal Information
Vol. 44. Issue 1.
Pages 27-33 (January - February 2020)
Download PDF
More article options
Vol. 44. Issue 1.
Pages 27-33 (January - February 2020)
Original article
Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: 2 Turkish hospital experience
Sunitinib versus pazopanib para el tratamiento del carcinoma de células renales metastásico: experiencia en 2 hospitales turcos
M. Ekenela,
Corresponding author
, S. Karabulutb, I. Cilb, A. Zırtıloglub, E. Aydına, D. Turalb
a Institute of Oncology, Istanbul University, Istanbul, Turkey
b Department of Medical Oncology, Bakirkoy Education and Research Hospital, Istanbul, Turkey
This item has received
Article information
Full Text
Download PDF
Figures (2)
Tables (4)
Table 1. Patient characteristics.
Table 2. Comparison of toxicity observed.
Table 3. Dose reductions and cessation during therapy.
Table 4. Efficacy and survival outcomes.
Show moreShow less

Sunitinib (SUN) and Pazopanib (PAZ) are two oral tyrosine kinase inhibitors (TKIs) against vascular endothelial growth factor (VEGF). Their efficacy and safety in metastatic renal cell carcinoma (mRCC) has been proven with phase III studies. However, real world data is limited. The objective of this study is to assess the clinical benefit of SUN and PAZ in routine practice.


We reviewed the medical records of seventy-nine mRCC patients treated with SUN (50 mg/day on 4/2-schedule) or PAZ (800 mg/day continuously). Patients were assessed retrospectively at two Turkish hospitals between 2006 and 2016.


For the entire cohort median age of patients was 60 (28–87) years and 70% of them were male. The objective response rate (ORR) and disease control rate (DCR) in SUN/PAZ groups were 34/37% (p = 0.96) and 78/87% (p = 0.046), respectively. With a median follow up duration of 15 months, median progression-free survival (PFS) and overall survival (OS) in SUN/PAZ groups were 8/8 months (p = 0.83) and 22/21 months (p = 0.53), respectively. The common all grade toxicities for SUN vs. PAZ were fatigue (59 vs. 74%), skin changes (44 vs. 44%), anemia (35 vs. 42%), hypothyroidism (37 vs. 19%; p = 0.02) and hypertension (33 vs. 50%). In patients treated with SUN, total grade 3–4 toxicities (mean number of toxic events per patients) were 0.71, whereas in patients treated with PAZ, total grade 3–4 toxicities were 0.11 (p < 0.001). SUN was associated with an increased incidence of grade 3–4 fatigue (p = 0.007), anemia (p = 0.001) and hypothyroidism that needed therapy (p = 0.02). Dose reduction in 49% and 24% of patients (p = 0.02), and treatment cessation in 37% and 26% of patients (p = 0.37) were required in the SUN and PAZ groups, respectively.


In our study, there was no difference in terms of survival outcomes between two agents. However, patients treated with SUN had more grade 3–4 adverse events which prompted dose reduction.

Metastatic renal cell carcinoma

Sunitinib (SUN) y Pazopanib (PAZ) son dos inhibidores orales de la tirosina kinasa (ITK) que actúan contra el factor de crecimiento endotelial vascular (VEGF, por Vascuar Endothelial Growth Factor). Su eficacia y seguridad en el carcinoma de células renales metastásico (CCRm) se ha demostrado con estudios de fase III. Sin embargo, la evidencia real es escasa. El objetivo de este análisis es evaluar el beneficio clínico de SUN y PAZ en la práctica clínica habitual.


Revisamos los registros médicos de 79 pacientes con CCRm tratados con SUN (50 mg/día en el régimen 4/2) o PAZ (800 mg/día continuo). Los pacientes fueron evaluados retrospectivamente en dos hospitales turcos entre 2006 y 2016.


La mediana de edad de toda la cohorte fue 60 (28–87) años y el 70% de ellos eran hombres. La tasa de respuesta objetiva (TRO) y la tasa de control de la enfermedad (TCE) en los grupos SUN/PAZ fueron 34/37% (p = 0.96) y 78/87% (p = 0.046), respectivamente. Con una mediana de seguimiento de 15 meses, las medianas de supervivencia libre de progresión (SLP) y de supervivencia general (SG) en los grupos SUN/PAZ fueron de 8/8 meses (p = 0,83) y 22/21 meses (p = 0,53), respectivamente. La toxicidad común entre SUN vs. PAZ incluía fatiga (59 vs. 74%), cambios en la piel (44 vs. 44%), anemia (35 vs. 42%), hipotiroidismo (37 vs. 19%; p = 0.02) e hipertensión (33 vs. 50%). En los pacientes tratados con SUN, la toxicidad total de grado 3–4 (número medio de eventos tóxicos por paciente) fue de 0,71, mientras que, en los pacientes tratados con PAZ, la toxicidad total de grado 3–4 fue de 0,11 (p < 0,001). SUN se asoció con una mayor incidencia de fatiga de grado 3–4 (p = 0.007), anemia (p = 0.001) e hipotiroidismo requiriendo tratamiento (p = 0.02). Fue necesario reducir la dosis en los grupos SUN y PAZ en el 49% y el 24% de los pacientes (p = 0,02), y el cese del tratamiento en el 37% y el 26% de los pacientes (p = 0,37), respectivamente.


en nuestro estudio no hubo diferencias en términos de supervivencia entre los dos agentes. Sin embargo, en los pacientes tratados con SUN se dieron más eventos adversos de grado 3–4, siendo necesaria la reducción de la dosis.

Palabras clave:
Carcinoma de células renales metastásico


These are the options to access the full texts of the publication Actas Urológicas Españolas (English Edition)

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe to

Actas Urológicas Españolas (English Edition)

Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos